Atlas Trials

A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma

Clinical trial NCT04416451 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04416451
Sponsor
Memorial Sloan Kettering Cancer Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Marginal Zone Lymphoma
Start date
2021-05-04
Primary completion
2027-06-01
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.